-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From: NMPA official website Saxaglipti is an efficient dipeptide-based peptide enzyme-4 (DPP-4) inhibitor that selectively inhibits DPP-4, raises endogenetic glucoglycline-like peptide-1 (GLP-1) and glucose-dependent insulin-released polypeptide (GIP) levels and regulates blood sugar, mainly for the treatment of type 2 diabetes in adults.
compared with traditional sugar-lowering drugs, THE DPP-4 inhibitors have the advantage of not increasing the risk of hypoglycemia, neutral weight effects, and good cardiovascular safety.
Shagritin was first developed by Shishi Shiguibao Pharmaceuticals and was approved by the FDA in 2009 for listing under the product name: Onglyza®/Anizer ®, which was acquired by AstraZeneca and approved to enter the Chinese market in May 2011 and has been included in The Health Care Category B list since 2017.
Currently, five varieties (unilateral) of DPP-4 inhibitors, including shagritin, are listed in China, and the remaining four varieties are Sigletin, Viglitin, Aglitin and Liglitin, all of which are listed in The Health Insurance Category B and are listed as domestic generics.
It is worth noting that Viglitin is one of the largest number of generic drug listed enterprises, in addition to the original research has been approved for the listing of 8 generic drugs in China, in the third batch of national collection with a maximum of 89% (non-difference ratio) of the decline in the winning bid.
approved DPP-4 inhibitors data as of September 28, 2020 Based on sample hospital data for 2012-2017, Shagritin's sales in China increased year by year, with sample hospital sales exceeding 40 million in 2017 and global sales reaching 4.5 billion.
data sources: Zhejiang Securities Insight database shows that shagritin tablets are currently in addition to the original research AstraZeneta, Jiangsu Osaikang (first imitation) and Zhengda Tianqing (two imitations) have been approved for listing, submitted to the listing application of enterprises in addition to Howson, qilu pharmaceutical;